Fulairui (Canagliflozin Tablets) and Fulaixin (Empagliflozin Tablets) are highly selective sodium-glucose cotransporter 2 (SGLT-2) inhibitors that, in addition to having clear glucose-lowering effects, reduce body weight, the risk of cardiovascular events and the progression of nephropathy in patients with diabetes
Light activity like walking is safe immediately after injection, but moderate to intense cardio is better delayed 24 hours or longer to allow medication absorption and side effect stabilization
Pharmacodynamics: Ipamorelin is a selective ghrelin (GHS-R1a) receptor agonist that stimulates growth hormone release with minimal impact on cortisol, prolactin, or appetite pathways
Dizziness Mild dizziness can occur, particularly when standing up quickly or after extended periods without eating
They can cause some side effects, like an upset stomach or diarrhea, and rarely, more serious issues like pancreatitis or thyroid problems